Kamada Overview

  • Year Founded
  • 1990

Year Founded

  • Status
  • Public

  • Employees
  • 380

Employees

  • Stock Symbol
  • KMDA

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $6.09
  • (As of Thursday Closing)

Kamada General Information

Description

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

Contact Information

Website
www.kamada.com
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Drug Discovery
Other Industries
Therapeutic Devices
Biotechnology
Stock Exchange
TAE
Corporate Office
  • Post Box 4081
  • 2 Holzman Street, Science Park
  • Rehovot 7670402
  • Israel
+972 00-000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kamada Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$6.09 $6.13 $4.04 - $6.32 $350M 57.5M 68.1K $0.14

Kamada Financials Summary

In Thousands,
USD
TTM 30-Sep-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV 306,419 164,273 199,664 192,816
Revenue 151,526 129,339 103,642 133,246
EBITDA 20,392 10,719 3,712 22,701
Net Income 6,170 (2,321) (2,230) 17,140
Total Assets 337,056 322,379 318,667 210,665
Total Debt 5,855 20,600 24,352 4,939
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Kamada Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Kamada‘s full profile, request access.

Request a free trial

Kamada Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing,
Drug Discovery
Rehovot, Israel
380 As of 2022
00000
0000 0000-00-00
000000000 00000

000000

e dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla p
0000000000000
Barcelona, Spain
00000 As of 0000
000.00
000000&0

000

ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incidid
0000000000000
Melbourne, Australia
00000 As of 0000
000
000000000 000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Kamada Competitors (4)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Grifols Formerly PE-Backed Barcelona, Spain 00000 000.00 000000&0
CSL Corporation Melbourne, Australia 00000 000 000000000 000
Orchard Therapeutics Formerly VC-backed London, United Kingdom 000 00000 000000&0 00000
Octapharma Corporation Lachen, Switzerland 00000
To view Kamada’s complete competitors history, request access »

Kamada Patents

Kamada Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3735263-A1 Methods and compositions for pre-emptive treatment of graft versus host disease Inactive 01-Jan-2018 000000000
US-20200330565-A1 Methods and compositions for pre-emptive treatment of graft versus host disease Inactive 01-Jan-2018 000000000
US-20210085765-A1 Methods and compositions for pre-emptive treatment of graft versus host disease Inactive 01-Jan-2018 000000000
EP-3735263-A4 Methods and compositions for pre-emptive treatment of graft versus host disease Inactive 01-Jan-2018 000000000 0
CA-3087421-A1 Methods and compositions for pre-emptive treatment of graft versus host disease Pending 01-Jan-2018 A61K38/57
To view Kamada’s complete patent history, request access »

Kamada Executive Team (25)

Name Title Board Seat Contact Info
Amir London Chief Executive Officer
Eran Nir Chief Operating Officer, Operations
Tal Waisman Chief Marketing Officer & QA Manager
Jonathan Ward Director of Facilities and Construction
Hanni Neheman Vice President
You’re viewing 5 of 25 executive team members. Get the full list »

Kamada Board Members (20)

Name Representing Role Since
000 0000000 00 Self Board Member 000 0000
00000 0000 Kamada Board Member 000 0000
00000 000000 Self Board Member 000 0000
00000000 0000 Self Board Member 000 0000
000000 0000000000 Kamada Board Member 000 0000
You’re viewing 5 of 20 board members. Get the full list »

Kamada Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kamada Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Kamada‘s full profile, request access.

Request a free trial

Kamada Investments (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Saol Therapeutics (Portfolio of Four Hyperimmune Commercial Products) 22-Nov-2021 000000000 00000 Buildings and Property 0000 0000
Blood and Plasma Research (Plasma Collection Center in Texas) 03-Mar-2021 Corporate Asset Purchase 00.000 Buildings and Property 0000 0000
To view Kamada’s complete investments history, request access »

Kamada ESG

Risk Overview

Risk Rating

Updated March, 18, 2023

26.14 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,605

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 870

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 386

Rank

00.00

Percentile

To view Kamada’s complete esg history, request access »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »